Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00110617 · ClinicalTrials.gov registry record · Phase 2
Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 212
- Enrollment target
NCT00110617 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 212 participants.
The verdict
NCT00110617, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 212 participants
- Enrollment target
Study Summary
This study will examine the long-term safety and efficacy of Deferasirox in patients with sickle cell disease and iron overload from repeated blood transfusions.
Interventions
- DRUG Deferoxamine (DFO)
- DRUG Deferasirox (ICL670)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 212 participants |
| Start Date | 2005-05 |
| Est. Completion | 2008-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00110617
The ClinicalTrials.gov registry entry for NCT00110617 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 212 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Deferoxamine (DFO) is the first listed.
NCT00110617 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00110617 about?
NCT00110617 is a clinical study titled "Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients". This study will examine the long-term safety and efficacy of Deferasirox in patients with sickle cell disease and iron overload from repeated blood transfusions.
What is the current status of trial NCT00110617?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 212 participants. The study started on 2005-05. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00110617?
The interventions under investigation include: Deferoxamine (DFO) (DRUG), Deferasirox (ICL670) (DRUG).
Who is sponsoring clinical trial NCT00110617?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.